Literature DB >> 20452057

Updates on the prevalence of body dysmorphic disorder: a population-based survey.

Ulrike Buhlmann1, Heide Glaesmer, Ricarda Mewes, Jeanne M Fama, Sabine Wilhelm, Elmar Brähler, Winfried Rief.   

Abstract

Body dysmorphic disorder (BDD) is characterised by a preoccupation with perceived defects in one's appearance, which leads to significant distress and/or impairment. Although several studies have investigated the prevalence of BDD, many studies have methodological limitations (e.g., small sample sizes and student populations), and studies on the prevalence of BDD in the general population are limited. In the current study, 2510 individuals participated in a representative German nationwide survey. Diagnostic and Statistical Manual of Mental Disorders, fourth edition (DSM-IV) criteria for BDD and associated characteristics such as suicidality and the prevalence of plastic surgeries were examined using self-report questionnaires. The prevalence of current BDD was 1.8% (N=45). Further, individuals with BDD, relative to individuals without BDD, reported significantly more often a history of cosmetic surgery (15.6% vs. 3.0%), higher rates of suicidal ideation (31.0% vs. 3.5%) and suicide attempts due to appearance concerns (22.2% vs. 2.1%). The current findings are consistent with previous findings, indicating that self-reported BDD is a common disorder associated with significant morbidity.

Entities:  

Mesh:

Year:  2010        PMID: 20452057     DOI: 10.1016/j.psychres.2009.05.002

Source DB:  PubMed          Journal:  Psychiatry Res        ISSN: 0165-1781            Impact factor:   3.222


  60 in total

1.  Modular cognitive-behavioral therapy for body dysmorphic disorder: a randomized controlled trial.

Authors:  Sabine Wilhelm; Katharine A Phillips; Elizabeth Didie; Ulrike Buhlmann; Jennifer L Greenberg; Jeanne M Fama; Aparna Keshaviah; Gail Steketee
Journal:  Behav Ther       Date:  2013-12-29

Review 2.  Visual processing in anorexia nervosa and body dysmorphic disorder: similarities, differences, and future research directions.

Authors:  Sarah K Madsen; Cara Bohon; Jamie D Feusner
Journal:  J Psychiatr Res       Date:  2013-06-27       Impact factor: 4.791

3.  Cued panic attacks in body dysmorphic disorder.

Authors:  Katharine A Phillips; William Menard; Andri S Bjornsson
Journal:  J Psychiatr Pract       Date:  2013-05       Impact factor: 1.325

4.  Pharmacotherapy Relapse Prevention in Body Dysmorphic Disorder: A Double-Blind, Placebo-Controlled Trial.

Authors:  Katharine A Phillips; Aparna Keshaviah; Darin D Dougherty; Robert L Stout; William Menard; Sabine Wilhelm
Journal:  Am J Psychiatry       Date:  2016-04-08       Impact factor: 18.112

Review 5.  Perceived ugliness: an update on treatment-relevant aspects of body dysmorphic disorder.

Authors:  Ulrike Buhlmann; Anna Winter
Journal:  Curr Psychiatry Rep       Date:  2011-08       Impact factor: 5.285

6.  Delusionality and response to open-label fluvoxamine in body dysmorphic disorder.

Authors:  K A Phillips; S L McElroy; M M Dwight; J L Eisen; S A Rasmussen
Journal:  J Clin Psychiatry       Date:  2001-02       Impact factor: 4.384

Review 7.  [Body dysmorphic disorder : Anxiety about deformity].

Authors:  T Gieler; E Brähler
Journal:  Hautarzt       Date:  2016-05       Impact factor: 0.751

8.  The phenomenology of self-reported body dysmorphic disorder by proxy.

Authors:  Jennifer L Greenberg; Martha Falkenstein; Lillian Reuman; Jeanne Fama; Luana Marques; Sabine Wilhelm
Journal:  Body Image       Date:  2013-02-04

9.  Abnormal brain network organization in body dysmorphic disorder.

Authors:  Donatello Arienzo; Alex Leow; Jesse A Brown; Liang Zhan; Johnson Gadelkarim; Sarit Hovav; Jamie D Feusner
Journal:  Neuropsychopharmacology       Date:  2013-01-15       Impact factor: 7.853

10.  Shame and Defectiveness Beliefs in Treatment Seeking Patients With Body Dysmorphic Disorder.

Authors:  Hilary Weingarden; Ashley M Shaw; Katharine A Phillips; Sabine Wilhelm
Journal:  J Nerv Ment Dis       Date:  2018-06       Impact factor: 2.254

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.